Lonza DonorPlex Hepatocytes

Lonza has launched DonorPlex Hepatocytes, a line of high-quality cryopreserved pooled donor suspension hepatocytes. Researchers within DMPK and ADME laboratories can now benefit from this robust product offering for studying the hepatic metabolism of drugs.

Understanding hepatic drug metabolism is necessary to meet the strict safety-testing requirements for market approval of new products. Researchers typically need to use primary cryopreserved hepatocytes from a large number of donors to obtain a statistically significant result. However, pooled donor hepatocytes currently available commonly suffer from increased lot-to-lot variability, while not being able to meet more specialised application needs.

Lonza’s manufacturing process is designed to ensure that the DonorPlex Hepatocytes exhibit improved phenotype reproducibility. Furthermore, a proprietary algorithm that predicts yield, viability and functional phenotype prior to manufacture ensures individual customer specifications are met, meaning the company can provide users with a variety of hepatocyte configurations and sizes that either represent the average population or meet specific metabolism testing and cytochrome P450 (CYP) activity needs.

The company offers a large, comprehensive inventory of cryopreserved single donor suspension hepatocytes, which include a range of 10-, 20- and 50-donor gender-specific and mixed-gender lots.